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Significance of the Study 
•	 This study compared the thyroid function and morphology of hyperlipidemic patients who received 
atorvastatin or rosuvastatin with those of a control group of non-statin-treated hyperlipidemic pa-
tients. There was an association between rosuvastatin treatment and reduction in thyroid volume and 
maximum nodule diameter. This could be a new treatment alternative for benign and malignant pro-
liferative thyroid diseases.
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Abstract
Objective: The objective of this study was to assess the anti-
proliferative pleiotropic effects of statins on thyroid func-
tion, volume, and nodularity. Subjects and Methods: One 
hundred and six hyperlipidemic patients were included in 
this prospective study. The 69 patients in the statin groups 
received atorvastatin (16 received 10 mg and 18 received 20 
mg) or rosuvastatin (20 received 10 mg and 15 received 20 
mg). The 37 patients in the control group, assessed as not 
requiring drugs, made only lifestyle changes. Upon admis-
sion and after 6 months, all patients were evaluated by ultra-
sonography as well as for lipid variables (total cholesterol, 
high- and low-density lipoprotein cholesterol, and triglycer-
ides) and thyroid function and structure. Results: After 6 
months, no differences in thyroid function, thyroid volume, 
the number of thyroid nodules, or nodule size were ob-
served in the statin and control groups. In a subgroup analy-
sis, total thyroid volume had decreased more in patients re-
ceiving 20 mg of rosuvastatin than that in the control group 
(p < 0.05). Maximum nodule size had decreased more in 
those receiving 10 mg of rosuvastatin (p < 0.05). Conclu-
sions: Our results suggest an association between rosuvas-
tatin treatment and smaller thyroid volume and maximum 
nodule diameter; this could be attributable to the antiprolif-
erative effects of statin therapy on the thyroid.
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Introduction 
Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme 
A (HMG-CoA) reductase enzyme, the rate-limiting step 
in cholesterol synthesis, and thus prevent cholesterol syn-
thesis through mevalonate [1]. The effects of statins apart 
from lipid reduction are known as pleiotropic effects and 
are believed to be attributable to the inhibition of meval-
onate and isoprenoid compound synthesis via the inhibi-
tion of HMG-CoA reductase [2, 3]. The mevalonate path-
way provides the bioactive molecules essential for numer-
ous cellular processes. The by-products of the mevalonate 
pathway, farnesyl pyrophosphate and geranylgeranyl py-
rophosphate, enable G proteins to be transported from 
within cells to the cell membranes and activated by post-
translational modification.
 The resultant activated proteins of the Ras super-fam-
ily participate in controlling processes such as cell prolif-
eration and differentiation, and the regulation of the actin 
cytoskeleton, membrane traffic, and nuclear transport. 
Many studies have shown that the mechanism responsi-
ble for statin pleiotropy is the inhibition of the Ras super-
family guanosine triphosphate (GTP)ases, which act as 
regulators in guanosine diphosphate/GTP transforma-
tion, and whose membrane localizations and functions 
depend on posttranslational protein isoprenylation [4–
6]. When the pleiotropic effects of statins were first rec-
ognized, various studies investigated their antitumor, an-
tiproliferative, and apoptotic effects [7–10]. 
Abnormal epithelial cell proliferation, which is com-
mon in thyroid tissue, may present as nodular or non-
nodular thyroid growth or neoplasia [11]. However, little 
is known about the pleiotropic effects of statins on thy-
roid cells. A possible thyroid-statin association was first 
reported in 1999, when Vitale et al. [12] showed in vitro 
that statins induce apoptosis in “multiplying thyroid 
cells” independently of p53, through protein synthesis 
and a mechanism based on caspase enzymes. Rat thyroid 
cells with Ras-transformation were found to be more sen-
sitive to HMG-CoA reductase inhibitors than normal 
cells. Ras mutation activation and other oncogenes are 
common in thyroid tumors; ras mutations may also be 
present in nodular hyperplasia of the thyroid [13, 14]. In 
a 2006 study performed on rats, Laezza et al. [15] showed 
that HMG-CoA reductase inhibitors inhibit propylthio-
uracil-induced goiter with p21 ras-MAPK (mitogen-acti-
vated protein kinase) pathway modulation. Thus, statins 
may offer a new treatment alternative for benign and ma-
lignant proliferative thyroid diseases. Only 2 retrospec-
tive and no prospective clinical studies on the pleiotropic 
effects of statins on the thyroid have been published in 
English [16, 17]. In this study, the objective was to pro-
spectively compare the change in thyroid function and 
morphology of hyperlipidemic patients receiving atorv-
astatin or rosuvastatin with those of a control group of 
non-statin-treated hyperlipidemic patients in a region 
with mild-to-moderate iodine deficiency. Thyroid vol-
ume and morphology are affected by iodine intake, with 
the incidence of goiter and nodules being higher in io-
dine-deficient regions [18, 19]. 
Subjects and Methods
Subjects
This prospective, controlled study took place from August 2012 
to March 2014 at the Department of Endocrinology and Metabo-
lism, Baskent University School of Medicine, Ankara, Turkey. The 
study was approved by the local institutional review board and 
written informed consent was obtained from all participants. 
One hundred and seventeen patients who presented to our hos-
pital and were diagnosed with hypercholesterolemia were en-
rolled. The National Cholesterol Education Program Adult Treat-
ment Panel (NCEP ATP) III guidelines [20] on drug treatment 
indications were used to plan the hyperlipidemia treatment. After 
assessment for the risk of coronary heart disease, 80 patients with 
indications for drug treatment and no exclusion criteria according 
to NCEP ATP III guidelines (despite a 4-week first-stage diet) were 
assigned to various “statin” groups. Exclusion criteria included 
previous statin treatment, a known current or previous thyroid 
disease, current levothyroxine replacement therapy, current or 
previous use of antithyroid drugs, radioactive iodine therapy, and 
current or previous use of drugs that may affect thyroid functions. 
Eleven patients were excluded from the drug intervention groups 
Table 1. Relevant characteristics of the study population
Control group
(n = 37)
Statins group
(n = 69)
p
Age, years 51.68±15 55.7±7.8 0.142
Sex
Female 24 (64.9) 38 (55.1) 0.409
Male 13 (35.1) 31 (44.9)
Weight, kg 76.8±15.3 77.5±12.9 0.810
BMI 27.8±4.2 28.5±4.2 0.414
Smoking status 7 (18.9) 19 (27.5) 0.554
Comorbidity
DM 4 (10.8) 38 (55.1) <0.001*
HT 11 (29.7) 38 (55.1) 0.015*
CHD 4 (10.8) 8 (11.6) 0.589
Values are expressed as means ± SD or n (%). DM, diabetes 
mellitus; HT, hypertension; CHD, coronary heart disease. * p < 0.05.
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because of lack of compliance. The control group comprised 37 
patients who were not given statins. The study was ultimately com-
pleted with 106 patients (37 controls and 69 in the statin group). 
Of these 106, 62 were female (58.5%) and 44 were male (41.5%). 
Their mean age was 53.22 ± 10.26 years (range 25–81 years). Forty-
two patients (39.6%) had type 2 diabetes (DM), 49 (46.2%) had 
hypertension (HT), and 12 (11.3%) had coronary heart disease. 
Their body mass index was 28.26 ± 4.29 and their rate of smoking 
was 24.5%. All patients were residing in Ankara, a region with 
mild-to-moderate iodine deficiency (Table 1) [21]. 
The 37 (34.9%) patients in the control group were prescribed 
lifestyle and dietary changes for their hyperlipidemia. Of the 69 
patients receiving drug treatment, 20 received rosuvastatin 10 mg 
(19.8%),15 received rosuvastatin 20 mg (14.9%),16 received ator-
vastatin 10 mg (15.8%), and 18 received atorvastatin 20 mg (17.8%). 
The mean rosuvastatin and atorvastatin dose was 14.3 and 21.7 mg, 
respectively.
Methods
Patients assessed as requiring statin treatment were assigned by 
a simple random sampling method to receive either atorvastatin 
(10–20 mg daily) or rosuvastatin (10–20 mg daily). The study 
groups were as follows: group 1 (assessed as not requiring statin 
treatment), were advised to make therapeutic lifestyle changes 
(n = 37), group 2 received rosuvastatin (n = 35: 20 received 10 mg 
[R10] and 15 received 20 mg [R20]), and group 3 received atorv-
astatin (n = 34: 16 received 10 mg [A10] and 18 received 20 mg 
[A20]). Patients receiving statins were also advised about thera-
peutic lifestyle changes [20]. 
The patients in the control group were scheduled for follow-up 
at 0 and 6 months and those in the statin groups at 0, 1, and 6 
months. Serum concentrations of low-density lipoprotein choles-
terol (LDL-c), high-density lipoprotein cholesterol (HDL-c), tri-
glycerides (TG), aspartate aminotransferase, alanine aminotrans-
ferase, gamma glutamyl transferase, creatine kinase, and thyrotro-
pin-stimulating hormone (TSH) were measured at admission and 
at 6 months. Concentrations of hepatic enzymes and creatine ki-
nase were measured in the first month of treatment in patients 
receiving statins. Total cholesterol, HDL-c, and TG concentrations 
were measured using enzymatic assay (Boehringer, Mannheim, 
Germany). LDL-c was calculated using the Friedewald formula: 
LDL-c = total cholesterol − (HDL-c + TG/5). Thyroid function 
was evaluated by measuring the relevant variables by immunoche-
moluminescence assays with an automated analyzer (Immulite 
2000; Diagnostic Products, Los Angeles, CA, USA). 
Thyroid ultrasonography was performed on all patients at ad-
mission and at 6 months by the same researcher (C.D.) using a 10-
MHz linear probe (Logic 5 Pro; GE Medical Systems, Madison, 
WI, USA). The size of the thyroid gland and each nodule identified 
was measured in 3 dimensions. The volume of the thyroid gland 
was calculated by using the following ellipsoid formula:
Volume (mL) = Depth (cm) × Width (cm) × Length (cm) × 
0.479 [22].
Statistical Analysis
Statistical analyses were performed by using SPSS for Windows 
v21.0. Mean values in independent groups were compared by us-
ing an independent-samples t test and means of nonparametric 
data with the Mann-Whitney U test. Rates of groups were com-
pared by using the χ2 test. Mean values in dependent groups were 
compared by using a paired-samples t test and means of nonpara-
metric data of dependent groups with the Wilcoxon test. p < 0.05 
was considered statistically significant. 
Results
The statin treatment groups did not differ significant-
ly from each other or the control group with respect to 
sex, age, weight, BMI, smoking status, or the presence of 
coronary heart disease. As expected, a statistically signifi-
cant greater proportion of patients had DM and HT in the 
drug treatment groups than in the control group. 
In addition to statin treatment, the routine use of 3 
other groups of drugs for longer than 6 months was also 
assessed: (a) drugs for DM (oral antidiabetic drugs in-
cluding metformin, sulfonylurea, glinide, acarbose, and 
gliptins as well as insulin and combination therapies); (b) 
drugs for HT (angiotensin-converting enzyme inhibitors, 
angiotensin receptor blockers, β blockers, calcium-chan-
nel blockers, and diuretics, or combinations thereof); and 
(c) acetylsalicylic acid, vitamin D, and omega-3. While all 
these drugs were used significantly less frequently in the 
control group than in the drug treatment groups, the drug 
subgroups did not differ in this respect. 
Table 2. Mean lipid concentrations before and after intervention in all groups
Control (n = 37) R10 (n = 20) R20 (n = 15) A10 (n = 16) A20 (n = 18)
baseline at 6 months baseline at 6 months baseline at 6 months baseline at 6 months baseline at 6 months
TC 230.5±18.7 208.8±19.3** 259.8±33.3 185.0±33.3** 302.7±52.3 214.6±44.1** 260.4±23.2 186.5±22.7** 277.4±42.1 205.3±27.6**
LDL-c 152.9±12.6 135.7±13.4** 176.6±25.3 105.5±25.8** 214.8±50.9 134.0±48.8** 180.1±19.3 113.9±24.7** 191.2±31.5 129.1±27.2**
HDL-c 47.1±9.4 47.6±9.1* 49.6±12.4 53.8±12.5** 50.8±17.2 54.2±21.0** 43.4±5.7 47.9±7.9** 45.3±11.7 47.3±11.7**
TG 152.5±65.9 127.7±52.8** 167.9±49.6 128.7±41.5** 185.0±109.6 131.8±54.4** 184.2±80.3 123.1±35.2** 204.3±108.3 144.3±61.7**
TSH 1.59±0.91 1.55±0.74* 1.96±0.97 1.72±0.79* 1.23±0.82 1.33±0.73* 1.96±0.89 1.98±0.85* 2.04±0.92 1.86±0.95*
Values are expressed as means ± SD. R10, rosuvastatin 10 mg; R20, rosuvastatin 20 mg; A10, atorvastatin 10 mg; A20, atorvastatin 20 mg; TC, total cholesterol; LDL-c, low-density 
lipoprotein cholesterol; HDL-c, high density lipoprotein cholesterol; TG, triglycerides; TSH, thyrotropin-stimulating hormone. * p < 0.05; ** p < 0.05.
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Following treatment, there were statistically signifi-
cant decreases from the levels at baseline of total choles-
terol, LDL-c, and TG, in both the control and treatment 
groups (p < 0.01). An apparent increase from baseline lev-
els in HDL concentrations was not statistically significant 
in the control group at the end of the study; however, 
these increases were statistically significant in the drug 
treatment groups (p < 0.05). No statistically significant 
changes were observed between pre- and posttreatment 
TSH concentrations in any group (Table 2).
Upon entry to the study, the mean total thyroid vol-
ume of all 106 patients was 12.46 ± 5.21 mL, and at 6 
months it was 12.39 ± 5.11 mL (p > 0.05), a nonsignificant 
change. Although there were no statistically significant 
changes in total thyroid volume at 6 months in groups 1, 
2 and 3, a significant reduction was seen in the R20 sub-
group of group 2 after treatment (p = 0.034; Table 3).
Nodules were detected in 43 (40.56 %) patients; 21 had 
single nodules and 22 had multiple nodules. The mean 
maximum nodule diameter upon entry was 6.62 ± 2.38 
mm in the control group and 10.31 ± 2.93 mm in the drug 
treatment groups. There was no change in the number of 
nodules at 6 months. 
The posttreatment maximum nodule diameter was 
6.72 ± 2.73 mm (a mean increase of 0.10 mm) in the con-
trol group and 9.98 ± 6.76 (a mean decrease of 0.33 mm) 
in the drug group; these changes were not statistically sig-
nificant. However, compared with the values at admis-
sion, a statistically significant decrease in maximum nod-
ule diameter was observed in the R10 group (n = 18) at 6 
months. Seven of these 18 patients had nodules with a 
mean diameter of 16.14 ± 9.5 mm at admission. Although 
the number of nodules did not change after treatment, the 
mean nodule diameter decreased to 15.42 ± 9.1 mm (p = 
0.047; Table 4). 
Discussion
This study found no statistically significant differences 
in TSH concentrations, thyroid volume, the number of 
nodules, or maximum nodule diameters between patients 
who did and did not receive statin treatment. 
At six months of treatment, there was no difference in 
the patients receiving the 2 types of statins. However, a 
comparison of the subgroups with the corresponding val-
ues in the control group revealed that total thyroid vol-
ume was significantly smaller in the R20 group (p < 0.05), 
and maximum nodule diameter significantly smaller in 
the R10 group (p < 0.05). The lack of reduction in the 
maximum nodule diameter in the R20 group could have 
been due to the smaller number of patients with nodules 
in this group (R10 n = 7 vs. R20 n = 4) or to the relatively 
short duration of the study or both. The effects on thyroid 
volume after 6 months of treatment with 20 mg rosuvas-
tatin are in agreement with data obtained from retrospec-
tive patient surveys and in vitro and in vivo animal stud-
ies, and they may be related to the antiproliferative and 
apoptotic effects of prenylation inhibition on the meval-
onate pathway [11, 12, 16, 17]. The number of nodules 
did not change with treatment.
First discovered in 1976 and in continuous use since 
1981, statins have pleiotropic effects that have been 
known and studied extensively for 15 years [23]. Most of 
these effects are associated with the inhibition of the mev-
alonate pathway [3, 4]. 
Vitale et al. [12] showed in vitro that statins induce 
apoptosis by multiplying thyroid cells independently of 
p53 through protein synthesis and a mechanism based on 
Table 3. Thyroid volume before and after intervention
Group Thyroid volume, mL p
pretreatment posttreatment
Control (n = 37) 12.4±4.4 12.4±4.46 0.97
R10 (n = 20) 13.2±8.7 13.1±8.5 0.16
R20 (n = 15) 12.0±4.3 11.5±4.0 0.03*
A10 (n = 16) 11.7±4.1 11.5±4.2 0.18
A20 (n = 18) 12.4±3.4 12.2±3.3 0.07
Values are expressed as means ± SD. R10, rosuvastatin 10 mg; 
R20, rosuvastatin 20 mg; A10, atorvastatin 10 mg; A20, atorvastatin 
20 mg. * p < 0.05.
Table 4. Mean maximum nodule diameter before and after inter-
vention
Group Maximum nodule diameter, 
mm
p
pretreatment posttreatment
Control (n = 11) 6.62±2.38 6.72±2.73 0.579
R10 (n = 7) 16.14±9.52 15.42±9.10 0.047*
R20 (n = 4) 9.50±4.65 8.92±4.67 0.331
A10 (n = 9) 6.88±2.47 6.66±2.39 0.447
A20 (n = 12) 9.75±6.60 9.53±6.59 0.229
Values are expressed as means ± SD. R10, rosuvastatin 10 mg; 
R20, rosuvastatin 20 mg; A10, atorvastatin 10 mg; A20, atorvastatin 
20 mg. * p < 0.05.
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caspase enzymes. Apoptosis, a process of the self-destruc-
tion of cells, may be physiological or pathological. An 
apoptotic pathway may be initiated by various cytokines, 
growth factors, hormone deficiencies, or drugs, via trig-
gering the apoptotic system threshold. Various genes are 
associated with the regulation of apoptosis. The p53 gene 
controls the RNA transcription of pro- and antiapoptotic 
genes and plays a key role in cell death [13, 24].
Lovastatin, an HMG-CoA reductase inhibitor, has 
been shown to induce apoptosis in malignant glial tumors 
and prostate stromal tumors [25, 26]. Lovastatin inhibits 
the reduction of HMG-CoA reductase to mevalonate, the 
precursor of isopentenyl pyrophosphate. It also prevents 
the formation of mevalonate, geranyl pyrophosphate, 
farnesyl pyrophosphate, and all-trans-geranylgeranyl py-
rophosphate, thus preventing these molecules from pro-
liferating with farnesyl and geranylgeranyl transferase, 
and also preventing the transfer of the Ras super-family 
(Rho, Raf, Rac, and Rap), which plays a role in major cel-
lular functions like cell adhesion or motility, to small 
GTP-binding proteins. It was observed that in cases of 
prenyl modification deficiency, small GTP-binding pro-
teins fail to form a complex with target proteins, and this 
disruption in their functions induces apoptosis.
To investigate the apoptotic effects of HMG-CoA re-
ductase inhibition on thyroid cell cultures, Vitale et al. 
[12] studied the effects of lovastatin on normal and neo-
plastic thyroid cells, and observed cellular rounding in 24 
h and DNA fragmentation and apoptosis in 48 h, in both 
normal and neoplastic cadaver thyroid cell series. When 
mevalonate and the protein synthesis inhibitor, cyclohex-
imide, were added, all effects of lovastatin were blocked 
in a dose-dependent manner. Their finding that lovas-
tatin is a potent inducer of apoptosis in multiplying thy-
roid cell cultures supports the contention that prenyl-
ation inhibitors may have therapeutic potential, not only 
in prostate cancers and prostatic hyperplasia, but also in 
the proliferative processes of the thyroid. 
In another study, rat thyroid cells with Ras-transfor-
mation were found to be more sensitive to HMG-CoA 
reductase inhibitors than normal cells. Ras mutation ac-
tivation and other oncogenes are common in thyroid tu-
mors, and ras mutations may also be present in the nodu-
lar hyperplasia of the thyroid. This suggests that statins 
have a potential use for treatment of benign and malig-
nant diseases of the thyroid [12, 14, 24]. 
Zhong et al. [24] studied the effects of lovastatin 
on apoptosis and the induction of differentiation in ana-
plastic thyroid carcinoma (ATC) cells refractory to con-
ventional treatments. As a result, a high dose (50 μM) of 
lovastatin was found to induce apoptosis, while smaller 
doses (25 μM) were seen to trigger cytomorphological 
differentiation. An increase in the expression of thyro-
globulin was also detected in the ATC cells. These results 
supported the use of HMG-CoA reductase inhibitors for 
redifferentiation in the treatment of ATC. In a more re-
cent study [27], this group demonstrated that lovastatin 
at lower concentrations exerted an antiproliferation ef-
fect on human ATC cells through increases of p27 medi-
ated by the reduction of Rho geranylgeranylation. These 
results suggested that lovastatin increases the levels of p27 
protein through actions on RhoA/ROCK signaling and 
ubiquitination pathways, and inhibited proliferation of 
ARO cells by increasing the level of p27 protein. They 
concluded that lovastatin exerts both antiproliferative 
and differentiation-inducing effects on human ATC cells, 
probably rendering them more sensitive to radioactive io-
dine therapy.
A preclinical study indicated that epidermal growth 
factor (EGF) is involved in the proliferation and migra-
tion of differentiated thyroid cancer [28]. Overexpression 
of EGF or EGF receptor (EGFR) was observed in most of 
the thyroid cancer cells including the ATC cells, and was 
associated with a poor prognosis in patients with meta-
static thyroid cancer. EGFR was therefore identified as a 
novel therapeutic target for treating patients with ATC 
[29, 30].
Several studies have demonstrated that lovastatin and 
simvastatin can inhibit cell adhesion, migration, and in-
vasion [31, 32]. Recently, it has been shown that EGF can 
induce Cyr61 expression through the activation of the 
EGFR/ERK/CREB signaling pathway, and that EGF-in-
duced Cyr61 is involved in the regulation of cell migra-
tion in ATC cells [33]. Combined treatment with lovas-
tatin and troglitazone markedly inhibited cell migration 
by inhibiting EGF-induced Cyr61 expression in ATC 
cells. The authors reported that these results may provide 
a useful future strategy in the treatment of ATC [34].
In a 2006 study conducted on rats, Laezza et al. [15] 
reported that HMG-CoA reductase inhibitors inhibited 
propylthiouracyl-induced goiter by p21 ras-MAPK path-
way modulation. Even though different molecular and 
genetic processes have been proposed, results show that 
lovastatin is an effective inhibitor in goitrogenesis with 
p21 ras farnesylation inhibition. The authors concluded 
that mevalonate pathway inhibition may create antipro-
liferative effects in both benign and malignant thyroid 
tissue.
The first clinical study on thyroid volume and nodule 
prevalence in dyslipidemia patients on statins was con-
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ducted in 2008 by Cappelli et al. [16]. They retrospective-
ly assessed 137 patients who had been using statins for at 
least 5 years, and found a reduction in thyroid volume, 
and the prevalence, number, and volume of nodules with 
HMG-CoA reductase inhibitor treatment. Nodule preva-
lence among patients who had been receiving various 
statin treatments in the previous 5 years was 36.3% where-
as the rate in a nontreatment control group was 67.9% 
(p < 0.001). Thyroid and nodule volumes were also sig-
nificantly smaller in the group that had received statins 
for a long time. 
In another retrospective study on 70 DM subjects who 
were on statins for long periods and lived in a region with 
iodine deficiency, no difference in thyroid size, or nodule 
prevalence, number, and volume was found between the 
drug and control groups (n = 98). However, when pa-
tients were grouped into age brackets, thyroid nodules 
were less prevalent in patients aged 60–65 years (n = 12) 
than in control patients in the same age bracket (n = 27) 
(33 vs. 70%, p = 0.04). These findings are thought to be 
associated with the possible antiproliferative effects of 
statins, an association believed to be weak in regions with 
iodine deficiency [17]. 
In vitro and in vivo studies on breast cancer and mela-
noma suggest that only hydrophobic statins have useful 
pleiotropic effects [35, 36]. However, Cappelli et al. [16], 
in a retrospective study on 137 patients on statins (104 on 
simvastatin [hydrophobic], 29 on atorvastatin [hydro-
philic], 1 on pravastatin, and 1 on rosuvastatin), did not 
detect a relationship between the number and volume of 
thyroid nodules and molecule type. While the duration of 
statin use is reportedly a stronger predictor than the daily 
dose for a reduction in the risk of developing prostate 
cancer, Shannon et al. [37] concluded that nodules are 
less prevalent among patients taking a greater mean daily 
dose, independent of duration. 
In our study, hydrophilic rosuvastatin (20 mg) had a 
significant effect on total thyroid volume. The maximum 
reduction in nodule diameter was observed in the R10 
group. The lack of a reduction in maximum nodule diam-
eter in patients in the R20 group may be attributable ei-
ther to the small number of patients with nodules (n = 4) 
in this group, or to the absence of a relationship between 
the pleiotropic effects of statins on the thyroid gland and 
the dosage. 
Very few published studies have focused on the rela-
tionship between the pleiotropic effects of statins and 
common thyroid diseases. Existing studies are in vitro 
studies, animal studies, case observations, or retrospec-
tive studies. We obtained results in 2 of our study groups 
that suggest that the antiproliferative effects of statins can 
result in smaller thyroid volumes and nodule diameters. 
Statins may thus have beneficial therapeutic effects in 
thyroid diseases. Our study was limited by its short dura-
tion and small case numbers.
Future monitoring studies with larger groups of pa-
tients and of longer duration are needed to fully under-
stand the molecular mechanisms of the action of prenyl-
ation inhibitors on antiproliferative and apoptotic path-
ways, and to determine the appropriate and usable 
molecules and daily dosages. Our findings support the 
possible use of HMG-CoA reductase inhibitors in the 
treatment of benign and malignant diseases of the thy-
roid. 
Conclusion
We compared the effects of 2 statins on thyroid func-
tion, volume, and nodule prevalence in a prospective, 
controlled setting. Posttreatment, we found a significant 
decrease in total thyroid volume in the R20 group and 
maximum nodule diameter in the R10 group compared 
with the changes in the control group. Rosuvastatin may 
exert antiproliferative effects on cells by inhibiting the 
mevalonate synthesis pathway and decreasing isoprenoid 
compound formation. 
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